Zealand Pharma major shareholder announcement: J O Hambro Capital Management
January 17, 2024 10:30 ET
|
Zealand Pharma
Company announcement – No. 4 / 2024 Zealand Pharma major shareholder announcement: J O Hambro Capital Management Copenhagen, Denmark, 17 January 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq:...
Zealand Pharma completes registration of capital increase
January 12, 2024 05:00 ET
|
Zealand Pharma
Company announcement – No. 3 / 2024 Zealand Pharma completes registration of capital increase NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES,...
Zealand Pharma major shareholder announcement: Avoro Capital Advisors LLC
January 10, 2024 11:15 ET
|
Zealand Pharma
Company announcement – No. 2 / 2024 Zealand Pharma major shareholder announcement: Avoro Capital Advisors LLC Copenhagen, Denmark, 10 January 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq:...
Zealand Pharma announces directed issue and private placement for gross proceeds of DKK 1.45 billion
January 08, 2024 15:45 ET
|
Zealand Pharma
Company announcement – No. 1 / 2024 Zealand Pharma announces directed issue and private placement for gross proceeds of DKK 1.45 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN...
Zealand Pharma to participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference on January 4th
January 02, 2024 02:00 ET
|
Zealand Pharma
Press Release – No. 1 / 2024 Zealand Pharma to participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference on January 4th Copenhagen, Denmark, January 2, 2024 – Zealand...
Total number of shares and voting rights in Zealand Pharma at December 29, 2023
December 29, 2023 11:00 ET
|
Zealand Pharma
Company announcement – No. 46 / 2023 Total number of shares and voting rights in Zealand Pharma at December 29, 2023 Copenhagen, Denmark, December 29, 2023 – Zealand Pharma A/S (“Zealand”)...
U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital hyperinsulinism for up to three weeks of dosing due to inspection findings at third-party manufacturing facility
December 23, 2023 04:47 ET
|
Zealand Pharma
Company announcement – No. 45 / 2023 U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital hyperinsulinism for up to three weeks of dosing due to inspection...
Zealand Pharma submits New Drug Application to the US FDA for glepaglutide in short bowel syndrome
December 22, 2023 04:30 ET
|
Zealand Pharma
Press release – No. 18 / 2023 Zealand Pharma submits New Drug Application to the US FDA for glepaglutide in short bowel syndrome Copenhagen, Denmark, December 22, 2023 – Zealand Pharma A/S...
Zealand Pharma enters into EUR 90 million finance agreement with the European Investment Bank
December 22, 2023 02:00 ET
|
Zealand Pharma
Press release No. 17 / 2023 Zealand Pharma enters into EUR 90 million finance agreement with the European Investment Bank Copenhagen, Denmark, December 22, 2023 – Zealand Pharma...
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
December 07, 2023 16:05 ET
|
Zealand Pharma
Company announcement – No. 44 / 2023 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons ...